Macquarie Group LTD Innoviva, Inc. Transaction History

Macquarie Group LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$10.73 - $13.6 $610,537 - $773,840	-56,900 Reduced 90.89%	5,700 $64,000
Q4 2022 Feb 21, 2023	SELL	$11.8 - $13.78 $314,470 - $367,237	-26,650 Reduced 29.86%	62,600 $829,000
Q3 2022 Nov 14, 2022	SELL	$11.61 - $15.22 $10,193 - $13,363	-878 Reduced 0.97%	89,250 $1.05 Million
Q1 2021 May 14, 2021	SELL	$11.06 - $12.87 $4,600 - $5,353	-416 Reduced 0.46%	90,128 $1.08 Million
Q2 2020 Aug 11, 2020	BUY	$11.49 - $15.26 $41,869 - $55,607	3,644 Added 4.19%	90,544 $1.27 Million
Q3 2019 Nov 14, 2019	BUY	$10.05 - $14.55 $351,750 - $509,250	35,000 Added 67.44%	86,900 $916,000
Q2 2019 Aug 14, 2019	BUY	$13.1 - $14.95 $679,890 - $775,905	51,900 New	51,900 $756,000
Q3 2018 Nov 15, 2018	SELL	$13.63 - $15.7 $14,993 - $17,270	-1,100 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$13.44 - $17.59 $14,784 - $19,349	1,100 New	1,100 $15,000
Q1 2018 May 11, 2018	SELL	$13.8 - $16.99 $350,520 - $431,545	-25,400 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$11.73 - $14.75 $178,296 - $224,200	15,200 Added 149.02%	25,400 $360,000
Q3 2017 Nov 08, 2017	BUY	$12.06 - $14.12 $123,012 - $144,024	10,200	10,200 $144,000

229

79.2M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.33B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.